Daily Medication Pearl: Maribavir (Livtencity)

Maribavir (Livtencity) is indicated for the treatment of adults and pediatric patients with post-transplant cytomegalovirus infection.

Medication Pearl of the Day: Maribavir (Livtencity)

Indication: Maribavir (Livtencity) is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients, 12 years of age and older and weighing at least 35 kg, with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. CMV is a genus of viruses in the order Herpesvirales, and is related to the viruses that cause chickenpox and infectious mononucleosis.

Insight:

  • Dosing: 400 mg (two 200 mg tablets) orally twice daily, with or without food.
  • Dosage forms: Tablets 200 mg of maribavir.
  • Adverse events: The most common adverse events (all grades, >10%) in subjects treated with maribavir were taste disturbance, nausea, diarrhea, vomiting, and fatigue.
  • Mechanism of action: The antiviral activity of maribavir is mediated by competitive inhibition of the protein kinase activity of human CMV enzyme pUL97, which results in inhibition of the phosphorylation of proteins.
  • Manufacturer: Takeda

Sources:

Layout 1 (takeda.com)

LIVTENCITY™ (maribavir) | Now Available